subject area of

• A brief review of the past and future of platelet P2Y12 antagonist  Academic Article
• A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial  Academic Article
• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (caprie)  Academic Article
• Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus  Academic Article
• An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the charisma trial  Academic Article
• Anti-platelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma  Academic Article
• Antiplatelet agents in cardiology: the choice of therapy  Academic Article
• Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart disease  Academic Article
• Antiplatelet drug therapy moderates immune-mediated liver disease and inhibits viral clearance in mice infected with a replication-deficient adenovirus  Academic Article
• Antiplatelet medications and their indications in preventing and treating coronary thrombosis  Academic Article
• Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B  Academic Article
• Antithrombotic therapy with intracoronary stenting  Academic Article
• Aspirin and clopidogrel resistance: An emerging clinical entity  Academic Article
• Aspirin to prevent cardiovascular disease: The association of aspirin dose and clopidogrel with thrombosis and bleeding  Academic Article
• Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment  Academic Article
• Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events  Academic Article
• Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease  Academic Article
• Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial  Academic Article
• Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the clopidogrel for the reduction of events during observation (credo) trial  Academic Article
• Bleeding, mortality, and antiplatelet therapy: Results from the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance (charisma) trial  Academic Article
• Bleeding-associated outcomes with preoperative clopidogrel use in on- and off-pump coronary artery bypass  Academic Article
• Can N-acetylcysteine reverse the antiplatelet effects of clopidogrel? An in vivo and vitro study  Academic Article
• Clinical implications of percutaneous coronary intervention-clopidogrel in unstable angina to prevent recurrent events (PCI-CURE) study: a US perspective  Academic Article
• Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the charisma trial  Academic Article
• Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial)  Academic Article
• Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: Rationale and design of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance (charisma) trial  Academic Article
• Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events  Academic Article
• Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: Subgroup analysis of the charisma randomized trial  Academic Article
• Clopidogrel and coronary stenting: what is the next question?  Academic Article
• Clopidogrel is associated with better in-hospital and 30-day outcomes than ticlopidine after coronary stenting  Academic Article
• Clopidogrel pretreatment in ST-elevation myocardial infarction patients transferred for percutaneous coronary Intervention  Academic Article
• Clopidogrel with aspirin is the optimal antiplatelet regimen for intracoronary stenting  Academic Article
• Comparison of long-term usefulness-of clopidogrel therapy after the first percutaneous coronary intervention or coronary artery bypass grafting versus that after the second or repeat intervention  Academic Article
• Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators  Academic Article
• Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: Results from the charisma trial  Academic Article
• Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: Systematic review and meta-analysis of randomized controlled trials  Academic Article
• Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention - a randomized controlled trial  Academic Article
• Economic evaluation of clopidogrel plus aspirin for secondary prevention of cardiovascular events in canada for patients with established cardiovascular disease: Results from the charisma trial  Academic Article
• Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with c-reactive protein  Academic Article
• Effect of clopidogrel on the rate and functional severity of stroke among high vascular risk patients a prespecified substudy of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management and avoidance (charisma) trial  Academic Article
• Effect of clopidogrel plus asa vs. Asa early after tia and ischaemic stroke: A substudy of the charisma trial  Academic Article
• Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention  Academic Article
• Effect of clopidogrel pretreatment on periprocedural rise in c-reactive protein after percutaneous coronary intervention  Academic Article
• Effects of clopidogrel on the pharmacokinetics of sibutramine and its active metabolites  Academic Article
• Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein iib/iiia inhibitor use  Academic Article
• Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance (charisma) study  Academic Article
• Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: Design and rationale of the gravitas trial  Academic Article
• Evolution of improved antithrombotic and antiplatelet agents: Genesis of the comparison of abciximab complications with hirulog and back-up abciximab events trial (cachet)  Academic Article
• Extracardiac vascular disease and effectiveness of sustained clopidogrel treatment  Academic Article
• High-sensitivity c-reactive protein and clopidogrel treatment in patients at high risk of cardiovascular events: A substudy from the charisma trial  Academic Article
• Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial  Academic Article
• Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis  Academic Article
• Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials  Academic Article
• Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting  Academic Article
• Influence of genetic polymorphisms on the effect of high-and standard-dose clopidogrel after percutaneous coronary intervention the gift (genotype information and functional testing) study  Academic Article
• Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial  Academic Article
• Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial  Academic Article
• Is there a clinically significant interaction between calcium channel antagonists and clopidogrel? Results from the clopidogrel for the reduction of events during observation (credo) trial  Academic Article
• Is there a clinically significant interaction between calcium channel antagonists and clopidogrel?: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial  Academic Article
• Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial  Academic Article
• Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein iib/iiia blockade compared to heparin with routine glycoprotein iib/iiia blockade - a replace-2 substudy  Academic Article
• Lack of evidence of a clopidogrel-statin interaction in the charisma trial  Academic Article
• Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention - results from the clopidogrel for the reduction of events during observation (credo) trial  Academic Article
• Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting  Academic Article
• Optimal timing for pre-treatment with before percutaneous the initiation of 300 mg clopidogrel coronary intervention  Academic Article
• Optimal treatment and current situation in reperfusion after thrombolysis for acute myocardial infarction  Academic Article
• Oral antiplatelet therapy for percutaneous coronary revascularization  Academic Article
• Patients with peripheral arterial disease in the charisma trial  Academic Article
• Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the charisma trial  Academic Article
• Percutaneous coronary intervention in diabetic patients with non-st-segment elevation acute coronary syndromes  Academic Article
• Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease  Academic Article
• Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to cyp2c19 genotype in patients with high on-treatment reactivity  Academic Article
• Platelet function monitoring in patients with coronary artery disease  Academic Article
• Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention a time-dependent analysis of the gauging responsiveness with a verifynow p2y12 assay: Impact on thrombosis and safety (gravitas) trial  Academic Article
• Platelet-mediated thrombosis and drug-eluting stents  Academic Article
• Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade  Academic Article
• Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin  Academic Article
• Relationship between activated clotting time and ischemic or hemorrhagic complications - analysis of 4 recent randomized clinical trials of percutaneous coronary intervention  Academic Article
• Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention an analysis from the clopidogrel for the reduction of events during observation trial  Academic Article
• Risk stratification for patients undergoing nonurgent percutaneous coronary intervention using n-terminal pro-b-type natriuretic peptide: A clopidogrel for the reduction of events during observation (credo) substudy  Academic Article
• Smoking, clopidogrel, and mortality in patients with established cardiovascular disease  Academic Article
• Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial  Academic Article
• Statins do not affect platelet inhibition with clopidogrel during coronary stenting  Academic Article
• Structures of cytochrome P450 2B4 complexed with the antiplatelet drugs ticlopidine and clopidogrel  Academic Article
• Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery  Academic Article
• Synthesis of biologically active piperidine metabolites of clopidogrel: determination of structure and analyte development  Academic Article
• Tailored antiplatelet therapy in a patient with ITP and clopidogrel resistance  Academic Article
• The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-q-wave myocardial infarctions  Academic Article
• The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: Results from the clopidogrel for the reduction of events during observation (credo) trial  Academic Article
• The future of antiplatelet therapy: optimizing management in patients with acute coronary syndrome  Academic Article
• The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease  Academic Article
• The relationship between cyp2c19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: The charisma genetics study  Academic Article
• The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis  Academic Article
• Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events - data from the evaluation of platelet iib/iiia inhibitor for stenting (epistent) trial  Academic Article
• Triple antiplatelet therapy does not increase femoral access bleeding with vascular closure devices  Academic Article
• Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival - results from the do tirofiban and reopro give similar efficacy outcome trial (target)  Academic Article
• Update on clinical trials of antiplatelet therapy for cerebrovascular diseases  Academic Article
• Variability in platelet responsiveness to clopidogrel among 544 individuals  Academic Article
• Variable response to antiplatelet therapy: what does it mean to clinicians?  Academic Article
• X-ray crystal structure of the cytochrome p450 2b4 active site mutant f297a in complex with clopidogrel: Insights into compensatory rearrangements of the binding pocket  Academic Article